Navigation Links
Orthokine Treatment is Effective for Knee Arthritis, Even After Two Years

Long-Term Clinical Study Confirms Effectiveness of Autologous Therapy

DUSSELDORF, Germany, August 5 /PRNewswire/ -- The results of a two-year representative study of knee osteoarthritis, published in the internationally renowned journal "Osteoarthritis and Cartilage", confirm the safety and effectiveness of Orthokine therapy, in which anti-inflammatory proteins obtained from the patient's own blood are injected into the arthritic joint.

Researchers at Heinrich Heine University in Dusseldorf compared three treatments to determine which one produces the best long-term results for treatment of knee osteoarthritis. A total of 310 patients received a series of injections one of Orthokine, hyaluronic acid (a joint lubricant), or a placebo (table salt solution). Because of the chronic nature of arthritis, long-term treatment effects are particularly important for sufferers.

Two years after the initial treatment, 188 of the 310 patients were still experiencing reduced pain and improved function of the affected joint. The Orthokine group had the fewest patients who went on to seek further treatment. Patients who received Orthokine treatment had the greatest improvements in VAS and WOMAC scores. For the WOMAC test in particular, the outcomes were as follows: Starting from an initial WOMAC score of 124, the Orthokine group saw a reduction to a score of 58, while the final WOMAC scores for the other two groups remained well above that at 88 and 84. "This study shows that Orthokine treatment is a safe alternative to conventional methods", says study physician Carsten Moser.

"Osteoarthritis and Cartilage" is a respected scientific journal (impact factor 4.017) that publishes only original, peer-reviewed research into new methods for the treatment of diseases of the locomotor system.

Further information:

Orthogen AG

Frau Daniele Voss

Graf-Adolf-Str. 41

40210 Dusseldorf

Tel.: +49(0)211-60-255-35

Fax: +49(0)211-38700-10


SOURCE Orthogen AG
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Post Your Comments:
(Date:11/27/2015)... DUBLIN , Nov. 27, 2015 Research ... of the "Global Intrauterine Devices Market 2015-2019" ... --> In this report, the author ... intrauterine devices market for 2015-2019. To calculate the market ... of following type of products: Hormonal IUDs and copper ...
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
(Date:11/26/2015)... November 26, 2015 ... nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie ... ) --> ... (Photo: ) ... Medisch Centrum (LUMC) blijkt ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... GKhair & Tibolli ... the San Juan Beauty Show held on November 8th and 9th at the Puerto ... media personalities, hair artists, renowned beauticians and top of the line fashion journalists. The ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... provider of enterprise Time and Attendance/Workforce Management cloud-based solutions, announced today that ... Program with competencies in the Application Development, demonstrating a “best-in-class” ability and ...
(Date:11/30/2015)... , ... November 30, 2015 ... ... Inc. are pleased to announce their strategic partnership at the Radiological Society ... Transcription Service, Inc., and Winscribe, global providers of cutting-edge dictation and speech-enabled ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... product dealer. Joining more than 30 HealthPostures’ dealers located throughout the United States, ... increase the number of corporate, industrial, manufacturing and government workers and organizational leaders ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... patented products, announces the Unstoppable Swappables, a household invention that provides an economical ... $2 billion a year and is growing at 2.6%," says Scott Cooper, CEO ...
Breaking Medicine News(10 mins):